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RNA polymerase III (Pol III) synthesizes tRNAs and other small noncoding RNAs to regulate protein synthesis. Dysregulation of
Pol III transcription has been linked to cancer, and germline mutations in genes encoding Pol III subunits or tRNA processing
factors cause neurogenetic disorders in humans, such as hypomyelinating leukodystrophies and pontocerebellar hypoplasia. Here
we describe an autosomal recessive disorder characterized by cerebellar hypoplasia and intellectual disability, as well as facial
dysmorphic features, short stature, microcephaly, and dental anomalies. Whole-exome sequencing revealed biallelic missense
alterations of BRF1 in three families. In support of the pathogenic potential of the discovered alleles, suppression orCRISPR-mediated
deletion of brf1 in zebrafish embryos recapitulated key neurodevelopmental phenotypes; in vivo complementation showed all four
candidate mutations to be pathogenic in an apparent isoform-specific context. BRF1 associates with BDP1 and TBP to form the
transcription factor IIIB (TFIIIB), which recruits Pol III to target genes.We show that disease-causingmutations reduce Brf1 occupancy
at tRNA target genes in Saccharomyces cerevisiae and impair cell growth.Moreover, BRF1mutations reduce Pol III–related transcription
activity in vitro. Taken together, our data show that BRF1 mutations that reduce protein activity cause neurodevelopmental
anomalies, suggesting that BRF1-mediated Pol III transcription is required for normal cerebellar and cognitive development.
[Supplemental material is available for this article.]
Three RNA polymerases synthesize the different classes of RNAs in
eukaryotic cells. Pol I synthesizes most ribosomal RNAs; Pol II
mRNAs and miRNAs; and Pol III in a variety of noncoding RNAs
with a structural and catalytic function, e.g., tRNAs, 7SK RNA, 5S
rRNA, andU6 snRNA (SchrammandHernandez 2002;White 2011;
Dieci et al. 2013). Pol II–dependent transcriptionhas attractedmost
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attention because itsmRNAproducts are protein coding, but recent
years have seen an increasing interest in Pol III transcription, not
least because of its implication in human disorders. Increased
Pol III–dependent transcription has been linked to cell trans-
formation and cancer (Marshall and White 2008; Cabarcas and
Schramm2011), and germlinemutations in components of the Pol
III or tRNA processing machinery have been associated with neu-
rogenetic disorders, such as pontocerebellar hypoplasia (PCH),
a heterogeneous group of severe, often lethal, progressive neuro-
degenerative conditions characterized by cerebellar hypoplasia,
progressive microcephaly, seizures, and profound developmental
impairment. At least 10 types of PCH are currently recognized,
and mutations causing the most prevalent subtypes, PCH2 and
PCH4, are predicted to lead to loss of function of tRNA splicing
endonuclease (TSEN); other PCH types display anomalies of tRNA
processing as well (Namavar et al. 2011; Akizu et al. 2013; Rudnik-
Sch€oneborn et al. 2014; Schaffer et al. 2014). However, the
pathomechanism leading to PCH is poorly understood in many
subtypes.
More recently, mutations in the catalytic Pol III subunits
POLR3A and POLR3B have been identified in syndromic hypo-
myelinating leukodystrophies, such as hypomyelination, hypo-
dontia, and hypogonadotropic hypogonadism (4H syndrome)
(Bernard et al. 2011; Saitsu et al. 2011; Tetreault et al. 2011). POLR3A
mutations lead to a decrease in POLR3A levels and are predicted to
interfere with the interaction with other Pol III subunits, which in
turn would perturb Pol III–mediated transcription; a similar mech-
anism has been postulated for POLR3B-associated leukodystro-
phies. Although the molecular pathophysiology of these diseases is
not fully understood, these findings suggest that an intact Pol III
apparatus is essential for cognitive development and the structural
and functional integrity of the cerebellum and white matter.
The basal Pol III transcription machinery requires the orches-
trated interaction of Pol III, a multiprotein enzyme consisting of 17
polypeptide subunits, TFIIIB (transcription factor IIIB), and TFIIIC
(White 2011; Vannini and Cramer 2012). These factors, as well as
the underlying mechanisms of transcription initiation, are con-
served in eukaryotes. TFIIIC recognizes and binds to specific se-
quence blocks in internal promoters (type 1 and 2 promoters) of
target genes, such as tRNA genes. TFIIIC then recruits TFIIIB, which
is usually composed of the B-related factor BRF1, B double prime 1
BDP1, and the TATA box-binding protein TBP, each of which is re-
quired for TFIIIB function in vitro (White 2011). TFIIIB recruits Pol
III for transcription initiation. For the transcription of human RNA
genes with external (type 3) promoters, such as U6 snRNA, BRF1 is
replaced by BRF2 in TFIIIB, and TFIIIC is not required (Schramm
and Hernandez 2002). Notably, TBP is a candidate gene for cogni-
tive disorders in humans (Rooms et al. 2006), and TBP polyglut-
amine expansions cause spinocerebellar ataxia type 17 (Nakamura
et al. 2001).
Here, we describe an autosomal recessive human syndrome
characterized by intellectual disability and cerebellar, dental, and
skeletal anomalies. We used whole-exome sequencing (WES)
(Bamshad et al. 2011) and in vivo and in vitro assays to provide
evidence that partial loss-of-function BRF1 mutations cause this
recognizable disease by impairing Pol III–mediated transcription.
Results
Clinical delineation of a cerebellar-facial-dental syndrome
By comparing the clinical features of three pairs of siblings (three
female and three male) (Fig. 1A–C) from three unrelated families,
we observed a striking clinical overlap pointing to a previously
undescribed disorder characterized by cerebellar hypoplasia, in-
tellectual disability, characteristic facial dysmorphisms, and dental
anomalies (Table 1; for the complete version of Table 1, see Sup-
plemental Material). In each of the three families, two affected
children were born to unaffected parents (Fig. 1C), suggesting
autosomal recessive inheritance. In family 3 with first-cousin
parents, Leber congenital amaurosis (LCA) segregated indepen-
dently from cerebellar hypoplasia in two siblings (Fig. 1C). The six
children affected by the cerebellar-facial-dental syndrome showed
similar dysmorphic features that included sparse eyebrows, wave-
shaped palpebral fissures, apparently low-set ears, malocclusion,
and prominent upper incisors (Fig. 1A). They had proportionate
short stature andmicrocephaly of prenatal onset, mild-to-moderate
intellectual disability with speech delay, scoliosis, and sparse hair
(Table 1). Three children had laryngeal stridor or laryngomalacia.
Cranial magnetic resonance imaging revealed a pattern that was
reminiscent of TSEN-related PCH, with a very thin corpus callosum,
a flattened brainstem, and cerebellar vermis hypoplasia; however,
the pons was relatively well formed (Fig. 1B). On skull and ortho-
panoramic x-rays, we saw bialveolar protrusion with prominent
alveolar processes as well as taurodontism, a specific malformation
of the pulp of molar teeth. Array-CGH did not detect causative copy
number variants.We refer to this syndrome as cerebellar-facial-dental
syndrome.
Identification of BRF1 mutations
We performedWES in one or two affected individuals from each of
the three families. Under the simplest assumption of genetic ho-
mogeneity for this rare autosomal recessive phenotypic constel-
lation, we filtered for variants in the same gene with a predicted
impact on protein function or RNA splicing that are rare in control
populations of European descent. Because of parental consan-
guinity in family 3 and the lack of consanguinity in families 1 and
2, we searched for a gene harboring a rare homozygous variant in
the affected individuals from family 3 and rare compound het-
erozygous (or homozygous) variants in the affected children in
families 1 and 2. Subsequent to WES analysis and filtering, there
was a single gene that contained biallelic mutations in all affected
children: BRF1. Each affected child had two variants that predicted
missense alterations, for a total of four distinct mutations. We
confirmed all four BRF1 alleles, as well as cosegregation with the
cerebellar-facial-dental syndrome, in each family by Sanger se-
quencing (Fig. 1C; Supplemental Fig. 1). In family 1, the affected
siblings were compound heterozygous for a maternally inherited
c.677C > T mutation and a paternally inherited c.776C > T muta-
tion, predicting p.Ser226Leu (S226L) and p.Thr259Met (T259M),
respectively. In family 2, the affected sisters had inherited a c.667C >
T mutation from their mother and carried a c.875C > A mutation
that was likely transmitted from their father, from whom no DNA
was available (Fig. 1C). These mutations predict p.Arg223Trp
(R223W) and p.Pro292His (P292H) missense alterations, respec-
tively. The two affected boys in family 3 were homozygous for the
c.677C > T (p.Ser226Leu) mutation that had been identified in
family 1. This mutation cosegregated with the cerebellar-facial-dental
syndrome in family 3, while LCA was caused by a homozygous
mutation in RDH12 (c.784dupG; p.Ala262Glyfs*11), a gene pre-
viously shown to bemutated in LCA (Janecke et al. 2004). The four
BRF1 mutations were absent from ethnically matched controls as
shown by sequencing and were not present or very rare in public
SNP databases (Table 2).
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The longest BRF1 isoform is a 677-amino-acid protein that,
together with TBP and BDP1, forms the transcription factor IIIB
(TFIIIB), which recruits Pol III to its templates and is involved in
promoter opening (White 2011). The N-terminal region of BRF1 has
a role inDNAbinding andPol III recruitment (Kassavetis et al. 1998),
is homologous to the Pol II transcription factor TFIIB, and contains
an N-terminal zinc ribbon domain and two cyclin domains (Khoo
et al. 2014). The BRF1 gene on human chromosome 14q32.33 en-
codes several functional isoforms, some of which lack the zinc rib-
bon domain (McCulloch et al. 2000). The four identified missense
alterations invariably affect amino acids that are evolutionarily
conserved, including in orthologs from mouse and zebrafish (Fig.
1D), but are not conserved in BRF2. In Saccharomyces cerevisiae, Brf1
(Colbert and Hahn 1992), Arg223, Thr259, and Pro292 are con-
served, whereas Ser226 is replaced conservatively by an alanine; for
clarity, we will use the human amino acid numbering henceforth.
Figure 1. BRF1mutations cause a cerebellar-dental-skeletal syndrome. (A) Patients 1 and 2 (family 1) at the ages of 12 and 10 yr, patients 3 and 4 (family 2) at
the ages of 10 and 4 yr, and patients 5 and 6 (family 3). Note characteristic facial dysmorphism and dental anomalies. (B) Brain MRI (top, sagittal scans; bottom,
coronal scans) of patients 1–4 (P1–P4) at the ages of 14 yr, 9 yr, 12 yr, and 18 mo, respectively, showing a thin corpus callosum (white filled arrows), flattened
brainstem (white unfilled arrows), and cerebellar hypoplasia (black unfilled arrows). (C ) Pedigrees of family 1 (left), family 2 (middle), and family 3 (right) with
genotypes for BRF1 missense alterations. In family 2, the p.Pro292His mutation was likely transmitted by the unaffected father who did not participate in the
study. In family 3, the two individuals denoted by an asterisk had Leber congenital amaurosis caused by a homozygous RDH12mutation. (D) Multiple sequence
alignment of BRF1 orthologs and human TFIIB showing evolutionary conservation of mutant BRF1 amino acid residues.
BRF1 mutations cause neurodevelopmental anomalies
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Functional analysis of brf1 in zebrafish
As a first test of the functional candidacy of BRF1, we sought an in
vivo model with a credible phenotypic surrogate. We noted that
all probands in our study have cerebellar hypoplasia and micro-
cephaly, both of which have beenmodeled previously in zebrafish
embryos for a variety of neurodevelopmental disorders (Golzio
et al. 2012; Dauber et al. 2013; Margolin et al. 2013; Bernier et al.
2014). We therefore turned to developing zebrafish embryos
and asked whether either suppression or overexpression of brf1
has an effect on neurogenesis, head size, and/or cerebellar
morphology.
Given that brf1 has two copies in the zebrafish genome due to
the teleost-specific genome duplication, we generated splice
blocking morpholinos (sbMOs) for both copies (brf1a and brf1b),
and we scored for neurogenesis by measuring the area of the optic
tectum, the area between the eyes as a surrogate for brain size, and
the cerebellar integrity. We note that while brf1a is known to be
expressed at multiple stages of development as well as in multiple
organs, little is known about brf1b in zebrafish. Our in-house RNA-
seq data that interrogate the transcripts expressed specifically in
the head of 5 d post fertilization (d.p.f) zebrafish embryos in-
dicated that brf1b has significantly increased expression when
compared to brf1a. Indeed, brf1b was expressed, on average, 11.59
CPM (counts per millionmapped reads), while brf1a expression was
4.32 CPM. In triplicate experiments scored by two investigators
masked to the injection cocktails, suppression of brf1a gave no ap-
preciable phenotypes (data not shown). In contrast, suppression of
brf1b with a MO against the donor site of exon 8 (MO#1) (Supple-
mental Fig. 2) resulted in a significant reduction of both the size of
the optic tectum (Fig. 2B9,D,F9,H) and the total area between the eyes
(Fig. 2B,C,F,G). Furthermore, we observed cerebellar hypoplasia as
determined by the lack of axons in the midline of the morphant
zebrafish cerebellum (Fig. 2B9,F9,I). We did not observe further overt
morphological abnormalities or developmental delay in the injected
embryos as judged by the shape and position of the heart, the ab-
sence of edema, the number and shape of somites, and the presence
of a normal swim bladder. The observed phenotypes were specific;
coinjection of MO and wild-type (WT) human mRNA was able to
rescue the phenotypes (Fig. 2B–D,F–I). To assess the functionality of
the alleles, we coinjectedMOwith humanmRNAbearing one of the
variants of interest (P292H, R223W, S226L, and T259M) at a time. In
the context of BRF1 isoform2 (Fig. 2E), P292H and R223W scored as
functionally nulls as they failed to rescue the reduction in head size
and optic tecta as well as the cerebellar hypoplasia (Fig. 2F–I), while
S226L and T259M scored as hypomorphic: The mutants were sig-
nificantlymore affected thanMO+WTbutnot as severe asMOalone.
Strikingly, testing of three of the alleles (R223W, S226L, T259M) in
isoform 1 showed them all to be benign (rescuewas indistinguishable
from WT) (Fig. 2A–D), suggesting that the effect of the mutations is
isoform specific. Overexpression of WT human BRF1 and human
P292H, R223W, S226L, or T259M BRF1 showed no difference in head
size, optic tecta, or cerebellar hypoplasia (Fig. 2G9,H9,I9).
To confirm the specificity of our assay, we designed a second
sbMO against the donor site of brf1b exon 6 (MO#2). Injections of
MO#2 recapitulated the results obtained with MO#1, showing
a reduction of head size and optic tecta as well as cerebellar dis-
organization phenotypes in 3 d.p.f. embryos; again, the pheno-
types could be at least partially rescued by coinjection of human
WT BRF1 mRNA (Supplemental Fig. 3). Further supplementing
these findings, we utilized the CRISPR system and induced aber-
rations in brf1b by CAS9/gRNA. In the F0 brf1bCas9/gRNA, we ob-
served phenotypes that are fully concordant with the brf1b mor-
phant phenotypes produced by both sbMOs (Supplemental Fig. 3).
We conclude that suppression of brf1 leads to phenotypes that
recapitulate key symptoms of the human pathology, arguing in
favor of the candidacy of this gene for disease pathogenesis.
BRF1 mutations affect cell growth
We next turned to the question of the precise effect of the dis-
covered missense alleles. Consistent with their predicted patho-
genic nature, yeast lacking the chromosomal BRF1 gene and
expressing BRF1 with mutations corresponding to R223W or
P292H did not grow in spot dilution tests (Fig. 3A), consistent with
loss of Brf1 function and similar to our zebrafish functional assay
in which R223W and P292H were classified as nulls. Yeast cells
transformed with plasmids containing BRF1 substitutions T259M
or S226L (as found in families 1 and 3) or A226S (reflecting the
human reference sequence) grew normally. We observed similar
results in liquid cultures (Supplemental Fig. 4). To mimic the
compound heterozygosity present in the families, we transformed
yeast with two distinct plasmids expressing the BRF1 variants
R223W/P292H or S226L/T259M. Whereas S226L/T259M yeast
showed essentially normal growth, the R223W/P292H combina-
tion was lethal (Fig. 3A). With respect to the mutations identified
in family 1, these results further supported the candidacy of human
biallelic BRF1 missense alterations causing the cerebellar-facial-dental
syndrome.
BRF1 mutations impair Pol III–dependent transcription
To investigate whether the altered BRF1 residuesmay be important
for DNA binding, we mapped the mutated BRF1 residues on the
known crystal structure of the homologous human TFIIB-TBP-
DNA complex (Tsai and Sigler 2000). Residues Arg223 and Thr259
are conserved in human TFIIB (Fig. 1D) and are predicted to contact
Table 2. BRF1 mutations
BRF1 mutation
(DNA)
BRF1 alteration
(protein)
Affected protein
domain
Frequency in
control chromosomes
(sequencing)
Frequency in
control chromosomes
(ESP-EVS) PolyPhen-2 prediction SIFT prediction
c.677C > T p.(Ser226Leu) Cyclin 2 0/200 0/12,994 Probably damaging Not tolerated
c.776C > T p.(Thr259Met) Cyclin 2 0/200 1/13,006 Probably damaging Not tolerated
rs373957300
c.667C > T p.(Arg223Trp) Cyclin 2 0/100 2/12,996
(heterozygous)
Probably damaging Not tolerated
rs370270828
c.875C > A p.(Pro292His)  0/100 0/13,006 Probably damaging Not tolerated
(ESP-EVS) National Heart, Lung and Blood Institute (NHLBI) Exome Sequencing Project Exome Variant Server.
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Figure 2. Functional annotation of variants in isoforms 1 and 2 of BRF1 and its effects on the head size, optic tectum size, and cerebellar formation in
zebrafish embryos. (A,E) Schematic representation of the location of BRF1 variants examined in zebrafish within each of the two isoforms evaluated:
isoform 1 (NP_001229717.1; 650 aa) and isoform 2 (NP_001229715.1; 584 aa). In purple are alleles that when tested are shown to be null, and in brown
are alleles that score as hypomorphs based on zebrafish assays. (B,B9) Dorsal views of control zebrafish embryos and embryos injected with brf1bMO, brf1b
MO +WT human BRF1, and brf1bMO + variant (R223W, S226L, or T259M) human BRF1 RNA in the context of isoform 1, respectively, at 3 d.p.f., stained
with anti-a acetylated tubulin. (B) Head sizemeasurements were taken using brightfield images (highlighted with a yellow outline in panel F). (B9) The area
of the optic tecta wasmeasured in the fluorescent images (highlightedwith a cyan oval in panel F9). (C,D) Bar graphs showing the relative head size (C ) and
the optic tecta area (D). Data are presented asmean6 SE. Two-tailed t-tests were performed to assess statistical significance. The embryos coinjected with
theMOand each of the variants were statistically different fromMOalone but not statistically different when compared to embryos injectedwithMO+WT
human BRF1, therefore scoring as benign. (F–I9) Functional assessment of the BRF1 missense variants in the context of isoform 2. Three d.p.f. embryos
injected with brf1bMO, brf1bMO + WT human BRF1, brf1bMO + variant human BRF1 RNA (P292H, R223W, S226L, or T259M), or variant human BRF1
RNA alone in the context of isoform 2were observed following stainingwith anti-a acetylated tubulin for head size (F) and for optic tecta area (F9), as well as
for cerebellar defects (F9; illustrated with a red dashed box where maximum disorganization is observed). (G–I9) Bar graphs showing average head size,
optic tecta area, as well as the percentage of embryos with cerebellar defects evaluated among each condition. To assess statistical significance among the
evaluated conditions, two-tailed t-tests were performed for head size and optic tecta, and x2 tests were performed for cerebellar disorganization to
evaluate statistical significance across the conditions. In the context of isoform 2, functional analysis using zebrafish show that P292H and R223W are null,
while S226L and T259M are hypomorphic alleles, showing an isoform-specific effect in which head size and optic tecta size are reduced and cerebellar
disorganization occurs. No significant effects were observed for any of the phenotypeswhen the variants themselves were overexpressed. Each experiment
was done at minimum in triplicate with at least 50 embryos per condition per replicate. (***) P-value # 0.001 relative to MO + WT; (e) P-value # 0.001
relative to controls; (y) P-value # 0.01 relative to MO.
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DNA (Fig. 3B). Residues Ser226 and Pro292 are not conserved in
human TFIIB and are predicted to be in the proximity of the DNA,
but not in direct contact (Fig. 3B). These modeling results sug-
gested that the BRF1mutationsmight affect BRF1 binding to DNA,
impair TFIIIB-mediated Pol III recruitment, and reduce Pol III–
mediated transcription.
To test whether the BRF1 mutations influence Pol III re-
cruitment to gene promoters in vivo, we performed chromatin
immunoprecipitation (ChIP) with tandem affinity purification
(TAP)–tagged versions of BRF1 variants on Pol III target genes in
yeast (Fig. 3C–E). Consistentwith our predictions, the BRF1 variant
T259M showed strongly decreased promoter occupancy at four
tested tRNA loci and a significant decrease in occupancy of the U6
snRNA promoter (Fig. 3D). The ChIP signals for TAP-tagged A226S
and S226L variantswere not different fromwild-type Brf1 (Fig. 3C).
Although the R223Wand P292H variants could not be tested due
to their lethal effect, these results indicate that at least one BRF1
alteration can affect occupancy of different Pol III promoters in
vivo.
Finally, to test whether the BRF1 mutations cause a tran-
scriptional defect, we used an established in vitro assay (Hahn and
Roberts 2000). This assay is based on a nuclear extract from
a temperature-sensitive yeast strain carrying the BRF1 substitution
p.Trp107Arg (W107R). Extracts from this strain are transcription-
ally inactive, but addition of recombinant Brf1 protein restores
activity on a template encoding the native SUP4 promoter. When
we used purified recombinant Brf1 variants in this assay, we ob-
served significantly less transcription for the BRF1 variant R223W
in comparison with the same concentration of WT Brf1 (Fig. 4).
Milder, but both significant and reproducible defects were ob-
served for T259M, P292H, A226S, and S226L. BRF1 variants com-
bining two mutations also showed transcriptional defects in this
assay (Fig. 4). Taken together, these results show that BRF1 muta-
tions identified in patients can impair transcription in a well-
controlled, in vitro transcription assay.
Discussion
Whereas intellectual disability can be due to mutations in syn-
aptic genes (Pavlowsky et al. 2012; Zoghbi and Bear 2012), recent
studies have highlighted impairments of basal cellular functions
and pathways such as transcription and translation in the
etiology of cognitive disorders and neurogenetic syndromes
(Najmabadi et al. 2011). Some examples include pontocerebellar
hypoplasias, Pol III–related leukodystrophies, X-linked in-
tellectual disability, and leukoencephalopathy with vanishing
white matter (Bugiani et al. 2010; Namavar et al. 2011; Borck
et al. 2012; Daoud et al. 2013). Complete inactivation of pro-
cesses such as translation initiation or tRNA transcription is not
compatible with life, suggesting that most disease-causing mu-
tations are hypomorphs.
Our identification and characterization of BRF1 mutations
causing the syndromic cerebellar-facial-dental phenotype is in line
with these observations. No mutant Brf1mouse has been reported
to our knowledge; in yeast, deletion of BRF1 is lethal (Colbert and
Hahn 1992). Accordingly, one of the missense variants we have
Figure 3. BRF1 mutations cause growth defects and reduced target promoter occupancy. (A) BRF1 mutations affect cell growth. Spot dilutions of the
variants introduced into a BRF1 knockout strain grown at 30°C. Wild-type (WT) and variant Brf1 were encoded on plasmids. For the combination of two
mutations, two plasmids were used, each harboring one mutation and a distinct marker. (5-FOA)5-fluoroorotic acid. (B) Three-dimensional modeling of
human BRF1missense alterations. The four identified amino acid substitutions weremapped to the structure of human TFIIB (green) in a complexwith TBP
(purple) and DNA (pdb code 1C9B) (Tsai and Sigler 2000). Amino acids affected by mutations in families 1 and 2 are shown in yellow and orange,
respectively. (C–E) BRF1 variants show a decreased occupancy of tRNA promoters in yeast. Fold enrichments of ChIP experiments performed with tandem
affinity purification (TAP)—tagged BRF1 variants in yeast. Data are presented asmean6 SD. (C ) Mutations A226S to serine or S226L show no effect on fold
enrichment compared to WT. (D) Mutation T259M leads to decreased fold enrichment on tRNA genes. (E) Combination of the two variants results in
amuch lower occupancy of the S226L and T259M variants. Summing up both signals results in less occupancy of the twomutated BRF1 than theWT BRF1.
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identified is recruited to a lesser extent than wild type to target
genes. Several other mutants have reduced transcriptional activity,
suggesting that in the context of this assay they behave as hypo-
morphs. BRF1mutations likely confer a specific phenotype; we did
not identify BRF1 mutations in three individuals with clinically
overlapping but distinct malformation syndromes or in seven in-
dividuals with genetically unresolved forms of PCH (data not
shown). However, there is compelling evidence for the pathoge-
nicity of the identified variants in the cerebellar-facial-dental
syndrome: BRF1was the only gene exome-wide that harbored very
rare or unique biallelic mutations in the three affected sibships.
These missense variants affect conserved amino acids that lie
within a predicted functional domain, and two of the affected
amino acids likely interact directly with DNA. In vivo experiments
in zebrafish embryos showed that suppression of brf1b phe-
nocopied some of the key pathognomonic features of the syn-
drome. Of note, while we cannot exclude a possible effect of
overexpression on the outcome of our zebrafish assays, the effects
of the variants seemed to be restricted to isoform 2 of BRF1. Thus
our results possibly illustrate an isoform-specific effect underlying
the phenotype and offer a plausible hypothesis about how muta-
tions in a ubiquitous, key component of the cellular machinery
can induce specific, albeit severe, phenotypes. Similar splice
isoform-specific pathogenic effects have been found in other disor-
ders (Sarparanta et al. 2012; Schulte et al. 2014), suggesting that
this mechanism might be a significant regulator of pleiotropy.
Previous studies have shown that full-length human BRF1 is the
canonical isoform in pol III transcription, and whether other iso-
forms, including isoforms lacking the evolutionary conserved Zn
ribbon domain such as isoform 2, are biologically active remains
unknown. Biochemical data indicate that overexpression of iso-
forms lacking the Zn ribbon domain
can induce BRF1–TBP interactions in
vitro and reconstitute transcription in
crude systems (McCulloch et al. 2000;
Schramm and Hernandez 2002). While
the in vivo role of different BRF1 isoforms
remains to be elucidated, our zebrafish
data provide further evidence of the
pathogenic nature of the four missense
variants.
Further studies showed each of the
missense variants to affect a variety of
relevant activities in yeast, including tar-
get gene promoter occupancy, in vitro
transcription, and cell growth. We do not
know the precise mechanism by which
BRF1 contributes to the phenotype in
humans. We note, however, that mouse
Brf1 is expressed in anatomical structures
that are relevant to the observed human
pathology: In situ hybridization of post-
natal day 56 mouse brain had previously
revealed prominent Brf1 expression in
the olfactory bulb, hippocampus, and the
Purkinje and granule cell layers of the
cerebellum (Allen Brain Atlas) (Sunkin
et al. 2013), underscoring the important
role of BRF1 in brain development.
We speculate that one plausible
pathomechanism underlying the cere-
bellar-facial-dental syndrome is a reduced
steady-state level of tRNAs that would be predicted to impair
translation elongation; thismay explain the growth defect in yeast
and contribute to short stature in the affected individuals.
Whether themajor drivers of the phenotype are tRNAs or other Pol
III–dependent transcripts remains to be determined. Finally, it is
also unknown why partial disruption of Pol III transcription leads
to organ- and tissue-specific phenotypes. There are ;450 nuclear
encoded tRNA genes in the human genome for only 61 anticodons.
It has been shown previously that up to 26% of tRNA genes are
active in one cell type versus another (Barski et al. 2010) and that
tRNA expression varies by asmuch as tenfold among human tissues
(Dittmar et al. 2006), suggesting the existence of active cell and
tissue-specific regulation of Pol III transcription (Oler et al. 2010).
Although the genome-wide architecture of Pol III–mediated tran-
scription in neurons or specific brain regions is unknown, a pilot
study using a microarray containing 42 probes for nuclear encoded
tRNAs and assaying their relative expression among eight human
tissues revealed a high overall tRNA expression level in brain
(Dittmar et al. 2006). This observation may partially explain the
vulnerability of brain regions toward impaired tRNA transcription
or processing.Whether other affected tissues, such as the teeth, also
show specific tRNA expression patterns remains to be investigated.
We note that dental anomalies such as delayed dentition, hypo-
dontia, oligodontia, and abnormally placed or shaped teeth are part
of the Pol III–related leukodystrophy syndromes 4H; ataxia, delayed
dentition, andhypomyelination (ADDH); and leukodystrophywith
oligodontia (LO) (Daoud et al. 2013). An alternative explanation for
the tissue-restricted phenotypes engendered by BRF1 dysfunction
might be a partial functional redundancy with BRF2. It has been
shown, however, that BRF1 and BRF2 are almost completely
mutually exclusive as components of TFIIIB under physiological
Figure 4. In vitro transcription defects caused by BRF1 mutations in yeast. (Top) A representative
gel of the in vitro transcription reaction using a nuclear extract harboring a deficient Brf1 protein
(p.Trp107Arg, W107R) that is impaired in Pol III–dependent transcription. Addition of WT Brf1 rescues
activity whereas the different Brf1 variants and the combinations present in the affected children show
a defect in transcription. Data are presented asmean6 SD. A quantification is shown in themiddle panel.
(*) P < 0.01; (**) P < 0.0001. The lower panel shows a twelve times excess of the Brf1 protein amount
used for this assay separated on an SDS gel.
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conditions (Moqtaderi et al. 2010), andwhether BRF2 can partially
compensate for defective BRF1 is unknown.
In conclusion, our study defines a syndrome with cerebellar
hypoplasia, intellectual disability, and growth retardation that is
caused by partial deficiency of the conserved Pol III transcription
factor BRF1. These results add an example to the short list of ge-
netic diseases caused by dysregulation of the Pol III machinery,
most of which predominantly affect the central nervous system
and suggest that improved understanding of the potential target
specificity provided by BRF1 might offer pathomechanistic clues.
Methods
Subjects
The study was performed with the approval of the University of
Ulm Ethics Committee. Affected individuals were evaluated at the
genetics outpatient clinics of the Bambino Gesu Children’s Hos-
pital, Rome (family 1); the Hospital S. Maria, Lisboa (family 2); and
IRCCS Casa Sollievo Della Sofferenza Hospital, San Giovanni
Rotondo andGiovanni XIII Hospital, Bari, Italy (family 3). Patients
were enrolled with written parental consent for participation in
the study. The clinical evaluation included medical history in-
terviews, a physical examination, and review of medical records.
Clinical information of affected individuals from the first two
families had been independently submitted to the web-based
Dysmorphology Diagnostic System (DDS) of the DYSCERNE
network (a European network of centers of expertise for dysmor-
phology) (Douzgou et al. 2014) by the respective attending genet-
icists (M.L.D. and B.D.; A.M.). After review of the clinical
information and pictures, the DDS Expert Panel (including B.D.)
concluded that the four affected individuals were likely affected by
a previously unreported autosomal recessive disorder. Blood sam-
ples were obtained from each participating individual, and geno-
mic DNA was extracted by standard procedures.
Whole exome and BRF1 sequencing
Families 1 and 2
Genomic DNA was enriched for exonic and adjacent splice site
sequences with the SeqCap EZ Human Exome Library v2.0 kit, and
libraries were run on an Illumina HiSeq 2000 Sequencer via
a paired-end 100-bp protocol (Hussain et al. 2013). For data anal-
ysis, the Cologne Center for Genomics Varbank pipeline v2.6 and
user interface was used. Primary data were filtered according to
signal purity by the Illumina Realtime Analysis (RTA) software
v1.8. Subsequently, the reads were mapped to the human genome
reference build GRCh37/hg19 (http://www.genome.ucsc.edu/)
using the BWA-SW alignment algorithm (Li and Durbin 2010.
GATK v.1.6 (McKenna et al. 2010) was used to mark duplicated
reads, perform a local realignment around short insertion and
deletions (indels), recalibrate the base quality scores, and call SNPs
and short indels. Mean coverage was >1003 in both exomes and
;90% of target bases were covered more than 303. In the target
regions, we detected 25,894 SNVs and 2004 short indels in the
family 1 individual and 35,642 SNVs and 2795 short indels in the
family 2 individual. Scripts developed in-house at the Cologne
Center for Genomics were applied to detect protein changes, af-
fected donor and acceptor splice sites, and overlaps with known
variants. Splice site variants were analyzed with a maximum en-
tropymodel (Yeo and Burge 2004).We filtered for high-quality rare
variants (MAF < 0.1%; based on the 1000 Genomes database, build
20110521 [The 1000 Genomes Project Consortium 2012] and the
NHLBI Exome Sequencing Project Exome Variant Server [EVS],
build ESP5400 [Tennessen et al. 2012]) with a predicted impact on
protein sequence or splicing. We also filtered against an in-house
database containing variants from 511 exomes from individuals
with epilepsy to exclude pipeline-related artifacts.
Family 3
WES and data analysis were performed as previously described
(Alfaiz et al. 2014). Briefly, exomes were captured using the Agilent
SureSelect human all exon V4 enrichment kit and sequenced on an
Illumina HiSeq platform. Variants were filtered based on adherence
to an autosomal recessive inheritance pattern, prediction by SIFT
(http://sift.jcvi.org/) (Kumar et al. 2009) and PolyPhen-2 (http://
genetics.bwh.harvard.edu/pph2/) (Adzhubei et al. 2010), and absence
from dbSNP129 (http://www.ncbi.nlm.nih.gov/projects/SNP/).
PCR and Sanger sequencing were performed according to
standard protocols for the validation of variants of interest and for
cosegregation studies. BRF1 mutation nomenclature is based on
transcript NM_001519.3 and RDH12 mutation nomenclature on
transcript NM_152443.2.
In vivo modeling in zebrafish
Reciprocal BLASTof the human BRF1 protein sequence against the
zebrafish genome identified two orthologs, suggesting that this
gene is duplicated in the zebrafish genome: brf1a (NP_956192.1,
60% identity, 72% similarity) and brf1b (NP_956183.1, 60%
identity, 72% similarity).We targeted each of these transcriptswith
a sbMO designed and obtained from Gene Tools. The MOs target
the donor site of exon 6 for brf1a sbMO (TATTTGAAGCTTACC
GATAGCTGGT), the donor site of exon 8 for brf1b sbMO
(AGCTGTGACATTCACCTTTTTCTCA), and the donor site of
exon 6 for brf1b sbMO#2 (GTCATTACAGGGAGACTTACCGACA).
For rescue experiments, human WT mRNAs of isoform 1 (NP_
001229717.1) and isoform 2 (NP_001229715.1) of BRF1 were
cloned into pCS2+ vector and transcribed in vitro using SP6
mMessage machine kit (Ambion). All variants were introduced
with Phusion high-fidelity DNA polymerase (New England
Biolabs) and custom designed mutagenesis primers and Sanger
sequence confirmed on a 3730 ABI sequencer. We injected 1 nL of
solution (12 ng MO and/or 200 pg of human mRNA, (WT, P292H,
R223W, S226L, or T259M) into one- to four-cell-stageWT zebrafish
embryos (Niederriter et al. 2013) and collected them at 3 d.p.f.,
fixed in Dent’s fixative overnight at 4°C. Standard immunohisto-
chemistry was then performed using control embryos and em-
bryos injected with brf1b MO, MO + WT human BRF1, and MO +
variant human BRF1 (P292H, R223W, S226L, or T259M) stained
with anti-a acetylated tubulin (T7451, mouse, Sigma-Aldrich, di-
lution 1:1000) as the primary antibody and Alexa Fluor (goat anti-
mouse IgG (A21207, Invitrogen, dilution 1:1000) as a secondary
antibody. Stained zebrafish were observed using the Nikon AZ100
Microscopewith aDS-Qi1MCdigital camera head. All experiments
were performed in triplicate (;200 embryos), and significance was
determined with a Student’s t-test.
CRISPR target sequences (brf1b: CATGCATGAATTCCGGC
GCA) were identified using crispr.mit.edu and cloned into pT7-
gRNA (Addgene) following the protocol described at http://www.
addgene.org/crispr/Chen/. gRNAs and mRNAs were synthesized by
a MEGAshortscript T7 kit (Ambion), and Cas9 mRNAs were synthe-
sized by mMESSAGE mMACHINE SP6 (Ambion). One hundred two
pictograms gRNA + 150 pg Cas9 mRNA were injected into one-cell
stage zebrafish and collected at 3 d.p.f in Dent’s fixative overnight at
4°C and stained as mentioned above.
For RNA sequencing (RNA-seq), total RNA from 5 d.p.f.
zebrafish heads was extracted using a TRIzol/chloroform protocol. Li-
braries were constructed using a customized version of strand-specific
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dUTP and run on an IlluminaHiSeq 2000 platform (Sugathan et al.
2014).
Yeast strains and growth assays
To introduce BRF1 mutations in yeast, the shuffle vector system
developed by Sikorski and Hieter was used (Sikorski and Hieter
1989). BRF1 mutations were introduced in the vector pRS315,
which contains yeast BRF1 expressed under the control of its own
promoter. Mutations were introduced using site-directed mutagen-
esis and confirmed by DNA sequencing. The identified mutations
from humans (h) were transferred to yeast (y). The corresponding
amino acid positions are as follows: hR223 = yR218, hS226 =
yA221, hT259 = yT254, and hP292 = yP288. For combinations of
two mutations, BRF1 variants T259M and S226L were cloned into
pRS314 vector and cotransformed with the S226L and T259M
mutations in the pRS315 vector, respectively. Plasmids were
transformed into the yeast strain SHY285 (gift from S. Hahn,
MATa, ade2D∷hisG, his3D200, leu2D0, lys2D0, met15D0, trp1D63,
ura3D0, brf1D∷HIS3/pSH524), andWT BRF1was replaced with the
mutant gene by plasmid shuffle at 30°C. The rescue plasmid
pSH524 contains a URA3marker (Ars Cen URA3, BRF1) (Hahn and
Roberts 2000). For the spotting assays, strains were grown over-
night in selective media, normalized to equal densities (107 cells/
200 mL), serially diluted (1:5), and spotted on YPD media or
selective media (Leu-, Leu/Trp-) supplemented with 5-fluoroorotic
acid (5-FOA; Carl Roth). Plates were incubated for 3 d at 30°C. For
the liquid assays, cultures were inoculated in selective media,
grown overnight and normalized to equal densities (OD600nm =
0.33).We used 3.5 mL of these dilutions to inoculate a 96-well plate
with 200 mL of liquid media (YPD and selective media supple-
mented with 5-FOA). Plates were incubated for 3 d at 30°C. As
a control strain we used WT BY4741 yeast.
Protein purification
Protein purification was performed essentially as previously de-
scribed (Alexander et al. 2004), withminormodifications. Proteins
were expressed in Escherichia coli BL21-Codon plus (DE3) RIL cells
in LB medium. Protein expression was induced in 2 l cultures with
1 mM IPTG at an OD600 of 0.7. Cells were grown for 3 h at 37°C
and harvested (20 min, 4000 rpm, 4°C). The pellet was washed
with 40 mL LB medium and flash-frozen in liquid nitrogen. The
cells were thawed on ice and resuspended in 50 mL lysis buffer (25
mM Tris/HCl at pH 7.5 and 25°C; 200 mM KCl; 12.5 mM MgCl2;
10% [v/v] glycerol; 1 3 PI). Subsequently, 0.8 mg lysozyme (Roth)
per 1mL lysatewas added and incubated rotating in the cold room.
After 10 min, 0.2% IGEPAL CA-630 (MP Biomedicals) was added
for further 5 min. For cell disruption, lysate was sonicated for 15
min, at 25% duty cycle and 40 output value. Brf1 in inclusion
bodies was washed twice in H.35 buffer (20 mM HEPES at pH 8.0
and 25°C; 350 mM KCl; 2 mM MgCl2; 1% NaOH; 20% [v/v] glyc-
erol; 0.1% [v/v] IGEPAL CA-630; 1 3 PI). Inclusion bodies were
extracted with 5 mL G6 buffer (100 mM Tris/HCl at pH 7.5 and
4°C; 6MGdmCl; 2mM b-mercaptoethanol) and rotation for 1 h at
4°C. The solution was bound in batch to 2.5 mL Ni-NTA bead
volume in G6 buffer overnight at 4°C. Beads were washed with
12.5mLG6 buffer and protein eluted in batch with three times 2.5
mL Ni-NTA elution buffer (100 mM Tris/HCl at pH 7.5 and 4°C;
6 M GdmCl; 10 mM b-mercaptoethanol; 500 mM imidazole; 1 3
PI). To the combined eluate, ZnSO4 and DTT were added to final
concentrations of 10 mM and 5 mM, respectively. Finally, the
denatured Brf1 was refolded via rapid dilution and dialysis. For
dilution, 100 mL of the eluate was placed in the lid of a 1.5-mL
Eppendorf tube containing 1 mL dialysis buffer (20 mM Tris ace-
tate 80% cation at pH7.5 and 4°C; 200mMKCl; 2mMMgCl2; 20%
[v/v] glycerol; 0.1% [v/v], IGEPAL CA-630; 1 3 PI), and the lid was
closed quickly. For every tube this could be repeated twice. After
flash dilution the protein was dialyzed in dialysis buffer for 2 h,
frozen in liquid nitrogen, and stored at 80°C. Usually the puri-
fication resulted in 30 mL of 0.4–0.8 mg/mL protein solution.
ChIP assay
For the ChIP assay, TAP-tagged BRF1 and its mutant variants were
introduced in the pRS315 vector, which contains BRF1 expressed
under the control of its own promoter. For combinations of the
mutations, S226L and T259Mwere cloned into pRS314 vector and
cotransformed with the TAP-tagged BRF1 variants T259M-TAP and
S226L-TAP in the pRS315 vector, respectively. ChIP experiments
were performed as previously described (Aparicio et al. 2005).
In vitro transcription assay
The Pol III–dependent in vitro transcription assay was performed as
described by Hahn and Roberts (2000), with minor modifications.
The nuclear extract was prepared as described by Seizl et al. (2011).
The template used contained the SUP4 gene from [159]  [+244]
with respect to the transcription start site of the tRNA. SUP4 encodes
a tyrosine tRNA. The 25mL transcription reaction contained 100mM
KOAc (pH 7.6), 20mMHEPES (pH 7.6), 1 mM EDTA, 5mMMgOAc,
2.5 mM DTT, 150 ng template, 192 mg phosphocreatine, 0.2 mg
creatine phosphokinase, 10URiboLock RNase inhibitor (Fermentas),
50mg temperature-sensitive nuclear extract harboring a temperature-
sensitiveW107Rmutation inBRF1, 40mMa-amanitin, and100ngof
recombinant protein where indicated. Proteins were added to the
transcription reactionmix for 5min before addition of 0.1mMNTPs.
The transcription reaction was carried out for 60 min at 30°C. The
RNA was isolated, and for primer extension, 0.125 pmol primer was
annealed for 45min at 60°C in20mL5mMTris (pH8.3), 75mMKCl,
1mMEDTA (pH 8.0). The sequence of the 59-Cy5 labeled primer was
TCTCCCGGGGGCGAGTCGAACGCCC. Two micrograms of Acti-
nomycin D was added before 0.25 units MuLV reverse transcriptase
in 60 mL 5 mM Tris (pH 8.3), 75 mM KCl, 4.5 mM MgCl2, 15 mM
DTT, and 0.1 mM dNTPs extended the primer. The resulting cDNA
was isolated by ethanol precipitation and resuspended in 4 mL 0.04
mg/mL RNase A and 4 mL formamide buffer (80% formamide, 25
mM EDTA, 1.5% bromphenolblue). Before loading, samples were
boiled for 2min at 95°C and put directly on ice. Samples were run on
a 7 M urea, 8% polyacrylamide (35:1) gel in 13 TBE for 45 min at
180 V. The gel was pre-run for 5–10min, and the pockets were rinsed
before loading. Gels were analyzed and quantified with a typhoon
scanner FLA9400 and ImageQuant Software (GE Healthcare).
Data access
The zebrafish RNA-seq data have been submitted to theNCBIGene
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been submitted to the NCBI ClinVar database (http://www.ncbi.
nlm.nih.gov/clinvar/) under accession numbers SCV000192004,
SCV000192005, SCV000192006, and SCV000195766.
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